Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance
Status:
Withdrawn
Trial end date:
2021-07-20
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well the combination of ibrutinib and venetoclax works in
treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to
ibrutinib alone. Both ibrutinib and venetoclax may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Giving ibrutinib and venetoclax together
after development of ibrutinib resistance may work better than discontinuing ibrutinib and
switching to other chemotherapy drugs.
Phase:
Phase 2
Details
Lead Sponsor:
Kerry Rogers
Collaborators:
Janssen Research & Development, LLC National Cancer Institute (NCI)